Scholarlink

Purpose <p>This study aimed to evaluate the prognostic significance of microvessel density (MVD), assessed by CD34 immunohistochemistry (IHC), and its correlation with radiological features and bevacizumab (BEV) treatment efficacy in newly diagnosed glioblastoma.</p> Methods <p>We retrospectively analyzed 41 patients with newly diagnosed glioblastoma. MVD was quantified using CD34 IHC, and patients were stratified into low and high MVD groups according to the cutoff value determined by receiver operating characteristic curve analysis (sensitivity, 76.5%; specificity, 75.0%; AUC, 0.725). Radiological characteristics—including relative cerebral blood flow (rCBF), peritumoral edema, and cystic components—were assessed. Survival outcomes were compared using Kaplan–Meier analysis. Treatment responses to temozolomide (TMZ) with or without BEV were evaluated in both MVD groups.</p> Results <p>Patients in the low MVD group exhibited significantly longer progression-free survival (PFS, <i>p</i> &lt; 0.001) and overall survival (OS, <i>p</i> &lt; 0.001) than those in the high MVD group. Low MVD was associated with significantly lower rCBF, less peritumoral edema, and a higher prevalence of cystic components. All six cystic-type cases were found in the low MVD group and showed favorable prognosis. The addition of BEV to TMZ significantly prolonged PFS in the high MVD group (<i>p</i> = 0.001) but not in the low MVD group, with no OS benefit observed in either group.</p> Conclusion <p>MVD serves as a prognostic biomarker and may help predict BEV treatment efficacy in glioblastoma. Combined with radiological features, MVD assessment could support more individualized therapeutic strategies. Further prospective studies using both CD34 protein and mRNA expression are warranted to validate these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microvessel density as a prognostic and predictive biomarker in newly diagnosed glioblastoma: correlations with radiological features and bevacizumab efficacy

  • 期刊论文

  • 发表日期：

    2025年9月9日

查看全文
  • Atsushi Kambe,
  • Ryoya Ochiai,
  • Karen Makishima,
  • Sachiko Yasuda,
  • Irfan Kesumayadi,
  • Tomohiro Hosoya,
  • Makoto Sakamoto,
  • Shinya Fujii,
  • Masamichi Kurosaki

摘要

Purpose

This study aimed to evaluate the prognostic significance of microvessel density (MVD), assessed by CD34 immunohistochemistry (IHC), and its correlation with radiological features and bevacizumab (BEV) treatment efficacy in newly diagnosed glioblastoma.

Methods

We retrospectively analyzed 41 patients with newly diagnosed glioblastoma. MVD was quantified using CD34 IHC, and patients were stratified into low and high MVD groups according to the cutoff value determined by receiver operating characteristic curve analysis (sensitivity, 76.5%; specificity, 75.0%; AUC, 0.725). Radiological characteristics—including relative cerebral blood flow (rCBF), peritumoral edema, and cystic components—were assessed. Survival outcomes were compared using Kaplan–Meier analysis. Treatment responses to temozolomide (TMZ) with or without BEV were evaluated in both MVD groups.

Results

Patients in the low MVD group exhibited significantly longer progression-free survival (PFS, p < 0.001) and overall survival (OS, p < 0.001) than those in the high MVD group. Low MVD was associated with significantly lower rCBF, less peritumoral edema, and a higher prevalence of cystic components. All six cystic-type cases were found in the low MVD group and showed favorable prognosis. The addition of BEV to TMZ significantly prolonged PFS in the high MVD group (p = 0.001) but not in the low MVD group, with no OS benefit observed in either group.

Conclusion

MVD serves as a prognostic biomarker and may help predict BEV treatment efficacy in glioblastoma. Combined with radiological features, MVD assessment could support more individualized therapeutic strategies. Further prospective studies using both CD34 protein and mRNA expression are warranted to validate these findings.